PARP inhibition in cancer therapy

This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.

Journals publishing in this area

1

Clinical Cancer Research

ISSN 1078-04321,056 articles in this topic

417h-index

1.39Impact

27.3KArticles

1.6MCitations

2

Gynecologic Oncology

ISSN 0090-8258824 articles in this topic

224h-index

1.36Impact

28.3KArticles

684.8KCitations